Blood protein may predict immunotherapy success in liver cancer
NCT ID NCT05263830
First seen Jan 06, 2026 · Last updated May 09, 2026 · Updated 26 times
Summary
This study is looking at whether a protein called Glypican-3, found in the blood, can help predict how well a common immunotherapy combination (Atezolizumab plus Bevacizumab) works in people with advanced liver cancer. Researchers will measure Glypican-3 levels before and during treatment in 240 adults. The goal is to find a simple blood test that helps doctors choose the best treatment for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.